Literature DB >> 23363931

Tissue engineering of blood vessels in cardiovascular disease: moving towards clinical translation.

Brooks V Udelsman1, Mark W Maxfield, Christopher K Breuer.   

Abstract

Tissue engineering focuses on the construction of three-dimensional neotissues from their cellular components. Neotissue can be used to repair or replace tissues that are missing, damaged, or diseased. Despite its relative youth, the field has undergone significant growth. Vascular tissue engineering is at the forefront in the translation of this technology, as tissue engineered vascular grafts have already been successfully implanted in children with congenital heart disease. The purpose of this report is to review the advances in the understanding of tissue engineered vascular grafts as the technology moves to clinical translation.

Entities:  

Mesh:

Year:  2013        PMID: 23363931     DOI: 10.1136/heartjnl-2012-302984

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  12 in total

1.  Differential outcomes of venous and arterial tissue engineered vascular grafts highlight the importance of coupling long-term implantation studies with computational modeling.

Authors:  Cameron A Best; Jason M Szafron; Kevin A Rocco; Jacob Zbinden; Ethan W Dean; Mark W Maxfield; Hirotsugu Kurobe; Shuhei Tara; Paul S Bagi; Brooks V Udelsman; Ramak Khosravi; Tai Yi; Toshiharu Shinoka; Jay D Humphrey; Christopher K Breuer
Journal:  Acta Biomater       Date:  2019-06-12       Impact factor: 8.947

Review 2.  Vascular diseases await translation of blood vessels engineered from stem cells.

Authors:  Rekha Samuel; Dan G Duda; Dai Fukumura; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2015-10-14       Impact factor: 17.956

3.  Engineering the mechanical and biological properties of nanofibrous vascular grafts for in situ vascular tissue engineering.

Authors:  Jeffrey J D Henry; Jian Yu; Aijun Wang; Randall Lee; Jun Fang; Song Li
Journal:  Biofabrication       Date:  2017-08-17       Impact factor: 9.954

Review 4.  Stem cell-derived vasculature: A potent and multidimensional technology for basic research, disease modeling, and tissue engineering.

Authors:  Justin Lowenthal; Sharon Gerecht
Journal:  Biochem Biophys Res Commun       Date:  2015-09-30       Impact factor: 3.575

5.  Novel application and serial evaluation of tissue-engineered portal vein grafts in a murine model.

Authors:  Mark W Maxfield; Mitchel R Stacy; Hirotsugu Kurobe; Shuhei Tara; Tai Yi; Muriel A Cleary; Zhen W Zhuang; Manuel I Rodriguez-Davalos; Sukru H Emre; Yasuko Iwakiri; Toshiharu Shinoka; Christopher K Breuer
Journal:  Regen Med       Date:  2017-12-07       Impact factor: 3.806

6.  New technologies for surgery of the congenital cardiac defect.

Authors:  David Kalfa; Emile Bacha
Journal:  Rambam Maimonides Med J       Date:  2013-07-25

Review 7.  The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential.

Authors:  Suzanne M Watt; Francesca Gullo; Mark van der Garde; Daniel Markeson; Rosalba Camicia; Cheen P Khoo; Jaap Jan Zwaginga
Journal:  Br Med Bull       Date:  2013-10-23       Impact factor: 4.291

Review 8.  Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease.

Authors:  Alexis Bosman; Michael J Edel; Gillian Blue; Rodney J Dilley; Richard P Harvey; David S Winlaw
Journal:  J Clin Med       Date:  2015-04-22       Impact factor: 4.241

9.  Potential of Newborn and Adult Stem Cells for the Production of Vascular Constructs Using the Living Tissue Sheet Approach.

Authors:  Jean-Michel Bourget; Robert Gauvin; David Duchesneau; Murielle Remy; François A Auger; Lucie Germain
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

10.  PlGF-MMP9-engineered iPS cells supported on a PEG-fibrinogen hydrogel scaffold possess an enhanced capacity to repair damaged myocardium.

Authors:  C Bearzi; C Gargioli; D Baci; O Fortunato; K Shapira-Schweitzer; O Kossover; M V G Latronico; D Seliktar; G Condorelli; R Rizzi
Journal:  Cell Death Dis       Date:  2014-02-13       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.